SLU-PP-332 (5 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: published murine studies used intraperitoneal administration twice daily at 25 to 50 mg/kg, which is an every day cadence rather than a weekly or every other day one. The daily mcg values in the table are expressed for a 25 g mouse and are split evenly across the two administrations. No reputable source supports once-daily subcutaneous use for this compound, and the subcutaneous route is not validated for it; where general subcutaneous technique is referenced, it comes from clinical best-practice resources rather than from any SLU-PP-332 study. At 5 mg/mL, both phase doses sit well inside a single U-100 insulin syringe at 12.5 units (0.13 mL) and 25 units (0.25 mL), so no dose in this protocol needs splitting into two injections. Standard handling applies at every administration: clean the vial stopper and the site with alcohol and allow it to dry completely, use a new sterile syringe, inject slowly and steadily, and rotate sites systematically to avoid local irritation and lipohypertrophy.

Results Timeline

Sequence described in the research record. Individual response varies.

• Within hours of a single dose: murine studies report acute activation of the aerobic-exercise transcriptional program, with increased mitochondrial respiration and fatty-acid oxidation in skeletal muscle.
• Weeks 1 to 2: 1,250 mcg per day, split into two intraperitoneal injections of 625 mcg, which is 12.5 units (0.13 mL) each at 5 mg/mL.
• Weeks 3 to 8: 2,500 mcg per day, split into two injections of 1,250 mcg, which is 25 units (0.25 mL) each.
• End of week 8: the cycle length used in the published studies, where endurance capacity, muscle oxidative capacity, and cardiometabolic phenotypes were assessed in mice.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 5 mg/mL, 1 unit = 0.01 mL » 50 mcg on a U-100 insulin syringe, so 625 mcg = 12.5 units (0.13 mL) and 1,250 mcg = 25 units (0.25 mL).

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C in dry, dark conditions, with moisture exposure kept to a minimum.
• Reconstituted: refrigerate at 2 to 8 °C and avoid freeze-thaw cycles.

• Allow vials to reach room temperature before opening to reduce condensation.
• Protect from light during storage and handling.

Supplies Needed

Planning below is based on the published 8 week cycle at twice daily administration, which reaches 2,500 mcg per day from week 3 onward and works out to 17.5 mg per week at steady state.

Peptide Vials (SLU-PP-332, 5 mg vial):

• The 8 week cycle uses 122.5 mg in total, which is about 25 vials at 5 mg each; extending the same daily amounts to 12 weeks uses 192.5 mg, about 39 vials, and to 16 weeks uses 262.5 mg, about 53 vials.

Insulin Syringes (U-100):

• Per week: 14 U-100 insulin syringes, at 2 injections per day, since each dose fits one syringe at this concentration.
• Full cycle: 112 syringes across 8 weeks, rising to 168 across 12 weeks and 224 across 16 weeks.

Bacteriostatic Water (10 mL bottles):

• Each 5 mg vial takes 1.0 mL of bacteriostatic water, so one 10 mL bottle covers 10 vials, which makes 3 bottles for the 8 week cycle, 4 for 12 weeks, and 6 for 16 weeks.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the site.
• Full cycle: 224 swabs across 8 weeks at 112 injections, which is three 100 count boxes, and 448 across 16 weeks.

Important Notes

Practical considerations for consistency and safety.

• No human data: SLU-PP-332 has never been tested in human subjects, and all evidence comes from murine models, so tolerability, pharmacokinetics, and adverse effects in people are unknown.
• At 1.0 mL per 5 mg vial, a reconstituted vial holds two days of dosing once the protocol reaches 2,500 mcg per day, so vials are reconstituted often and each one is dated and labelled with its concentration at the time it is mixed.
• Use a new sterile syringe for every administration and dispose of it in a sharps container; rotate sites to reduce local irritation.
• Document administration times, doses, and observations, since the murine protocols this page reflects depend on standardized recording for reproducible results.
• The published route is intraperitoneal. Subcutaneous administration is not validated for this compound, and no source supports substituting a once-daily subcutaneous schedule for the twice daily published one.
• Regulatory Note: SLU-PP-332 is not approved by any regulatory agency for human use and has never entered human trials. It is sold and handled for research purposes only and is not for human consumption. The master sheet lists no WADA status for this compound.

How This Works

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERR alpha, ERR beta, and ERR gamma), with strongest activity at ERR alpha. In murine studies, acute administration activated an aerobic-exercise transcriptional program, increased mitochondrial respiration and fatty-acid oxidation in skeletal muscle, and improved endurance capacity and cardiometabolic phenotypes. The compound acts as an exercise mimetic by engaging the metabolic pathways typically switched on during physical training, without the mechanical stress of actual exercise. All evidence to date is preclinical.

Benefits & Side Effects

Observations from the published record.

• Metabolic effects: enhanced mitochondrial function, increased fatty-acid oxidation, and improved glucose tolerance in diet-induced obese mice.
• Cardiac effects: ameliorated heart failure through enhanced cardiac fatty-acid metabolism and mitochondrial function in preclinical models.
• Endurance: increased treadmill running capacity and muscle oxidative capacity in mice.
• Renal effects: reversed mitochondrial dysfunction and inflammation in aging kidney models.
• Human safety unknown: no data exist on human tolerability, pharmacokinetics, or adverse effects, which is the single largest gap in the evidence base.
• Route caveat: every reported finding comes from intraperitoneal dosing in mice, so none of it transfers directly to any other species or route.

Lifestyle Factors

Complementary strategies for best outcomes.

• Diet composition, standard compared with high-fat, influenced metabolic outcomes in the published studies.
• SLU-PP-332 was studied alongside exercise training in some murine models, which suggests potentially synergistic effects rather than a replacement for training.
• Environmental controls such as temperature and housing are standardized in research protocols, since they shift metabolic readouts on their own.
• Compound stability and handling procedures are critical for reproducible results, which makes consistent reconstitution, refrigeration, and light protection part of the protocol rather than an afterthought.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry completely.
2. For subcutaneous administration: pinch a skinfold; insert needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
5. Note: Published murine studies used intraperitoneal administration; subcutaneous route is not validated for this compound.

References

Source citations for further reading.

1. Synthetic ERR alpha/beta/gamma Agonist Induces ERR alpha-Dependent Acute Aerobic Exercise Response (ACS Chemical Biology, 2023).
2. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhanced Cardiac Fatty Acid Metabolism (Circulation, 2024).